Prognostic value of c-MET in head and neck cancer: A systematic
review and meta-analysis of aggregate data

J 2017

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data

SZTURZ, Petr, Marie BUDÍKOVÁ, Jan B. VERMORKEN, Ivanka HOROVÁ, Břetislav GÁL et. al.

Základní údaje

Originální název

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data

Autoři

SZTURZ, Petr (203 Česká republika, garant, domácí), Marie BUDÍKOVÁ (203 Česká republika, domácí), Jan B. VERMORKEN (56 Belgie), Ivanka HOROVÁ (203 Česká republika, domácí), Břetislav GÁL (203 Česká republika, domácí), Eric RAYMOND (250 Francie), A. de GRAMONT (250 Francie) a Sandrine FAIVRE (250 Francie)

Vydání

Oral oncology, AMSTERDAM, ELSEVIER SCIENCE BV, 2017, 1368-8375

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.636

Kód RIV

RIV/00216224:14110/17:00099947

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.oraloncology.2017.09.009

UT WoS

000414323200011

Klíčová slova anglicky

c-MET receptor; Head and neck cancer; Immunohistochemistry; Overexpression; Prognostic factor; Predictive factor

Štítky

EL OK, podil

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 18. 3. 2018 16:58, Soňa Böhmová

Anotace

V originále

Objectives: The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) ligand/receptor axis has been implicated in pathogenesis of malignant diseases including squamous cell carcinoma of the head and neck (SCCHN). Overexpression of c-MET has been reported as a common molecular abnormality in SCCHN, although its prognostic and predictive value remains to be validated. Methods: We systematically searched literature for studies evaluating c-MET expression on immunohistochemistry in newly diagnosed, non-metastatic SCCHN. The c-MET expressing cases were classified into three categories according to predefined cut-off values for positivity. Our aim was to assess the prevalence of c-MET expression and its relationship with selected clinicopathological variables. Results: Twenty-eight studies with 2019 cases were included. Relative frequencies of c-MET expression above cut-off levels I, II, and III were 81.8%, 63.8%, and 46.2%, respectively. Differences between these three values were statistically significant (p < 1.0 x 10(-6)). Above cut-off level II, c-MET positivity was associated with worse overall survival (p = 4.0 x 10(-6)), positive nodal status (p = 1.0 x 10(-4)), higher disease stage (p = 7.0 x 10(-4)), older age (p = 2.1 x 10(-3)), disease recurrence (p = 2.0 x 10(-2)), and primary tumour localization in the oral cavity (p = 2.3 x 10(-2)). Above cut-off level III, c-MET positivity was associated with worse disease-free or progression-free survival (p = 9.0 x 10(-6)), p16 negativity ( p = 2.4 x 10(-4)), worse overall survival (p = 4.0 x 10(-4)), positive epidermal growth factor receptor (EGFR) status (p = 7.2 x 10(-4)), and larger primary tumours (p = 4.6 x 10(-3)). Conclusion: In SCCHN, immunohistochemical overexpression of c-MET above cut-off levels III and particularly II was associated with inferior survival outcomes and advanced disease. Moreover, it represents a promising predictive biomarker for c-MET targeting, yet the optimal scoring method remains to be defined.

Citovat

SZTURZ, Petr, Marie BUDÍKOVÁ, Jan B. VERMORKEN, Ivanka HOROVÁ, Břetislav GÁL, Eric RAYMOND, A. de GRAMONT a Sandrine FAIVRE. Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data. Oral oncology. AMSTERDAM: ELSEVIER SCIENCE BV, 2017, roč. 74, NOV 2017, s. 68-76. ISSN 1368-8375. Dostupné z: https://dx.doi.org/10.1016/j.oraloncology.2017.09.009.

@article{1407639,
   author = {Szturz, Petr and Budíková, Marie and Vermorken, Jan B. and Horová, Ivanka and Gál, Břetislav and Raymond, Eric and Gramont, A. de and Faivre, Sandrine},
   article_location = {AMSTERDAM},
   article_number = {NOV 2017},
   doi = {http://dx.doi.org/10.1016/j.oraloncology.2017.09.009},
   keywords = {c-MET receptor; Head and neck cancer; Immunohistochemistry; Overexpression; Prognostic factor; Predictive factor},
   language = {eng},
   issn = {1368-8375},
   journal = {Oral oncology},
   title = {Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data},
   volume = {74},
   year = {2017}
}

TY  - JOUR
ID  - 1407639
AU  - Szturz, Petr - Budíková, Marie - Vermorken, Jan B. - Horová, Ivanka - Gál, Břetislav - Raymond, Eric - Gramont, A. de - Faivre, Sandrine
PY  - 2017
TI  - Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data
JF  - Oral oncology
VL  - 74
IS  - NOV 2017
SP  - 68-76
EP  - 68-76
PB  - ELSEVIER SCIENCE BV
SN  - 13688375
KW  - c-MET receptor
KW  - Head and neck cancer
KW  - Immunohistochemistry
KW  - Overexpression
KW  - Prognostic factor
KW  - Predictive factor
N2  - Objectives: The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) ligand/receptor axis has been implicated in pathogenesis of malignant diseases including squamous cell carcinoma of the head and neck (SCCHN). Overexpression of c-MET has been reported as a common molecular abnormality in SCCHN, although its prognostic and predictive value remains to be validated. Methods: We systematically searched literature for studies evaluating c-MET expression on immunohistochemistry in newly diagnosed, non-metastatic SCCHN. The c-MET expressing cases were classified into three categories according to predefined cut-off values for positivity. Our aim was to assess the prevalence of c-MET expression and its relationship with selected clinicopathological variables. Results: Twenty-eight studies with 2019 cases were included. Relative frequencies of c-MET expression above cut-off levels I, II, and III were 81.8%, 63.8%, and 46.2%, respectively. Differences between these three values were statistically significant (p < 1.0 x 10(-6)). Above cut-off level II, c-MET positivity was associated with worse overall survival (p = 4.0 x 10(-6)), positive nodal status (p = 1.0 x 10(-4)), higher disease stage (p = 7.0 x 10(-4)), older age (p = 2.1 x 10(-3)), disease recurrence (p = 2.0 x 10(-2)), and primary tumour localization in the oral cavity (p = 2.3 x 10(-2)). Above cut-off level III, c-MET positivity was associated with worse disease-free or progression-free survival (p = 9.0 x 10(-6)), p16 negativity ( p = 2.4 x 10(-4)), worse overall survival (p = 4.0 x 10(-4)), positive epidermal growth factor receptor (EGFR) status (p = 7.2 x 10(-4)), and larger primary tumours (p = 4.6 x 10(-3)). Conclusion: In SCCHN, immunohistochemical overexpression of c-MET above cut-off levels III and particularly II was associated with inferior survival outcomes and advanced disease. Moreover, it represents a promising predictive biomarker for c-MET targeting, yet the optimal scoring method remains to be defined.
ER  -

SZTURZ, Petr, Marie BUDÍKOVÁ, Jan B. VERMORKEN, Ivanka HOROVÁ, Břetislav GÁL, Eric RAYMOND, A. de GRAMONT a Sandrine FAIVRE. Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data. \textit{Oral oncology}. AMSTERDAM: ELSEVIER SCIENCE BV, 2017, roč.~74, NOV 2017, s.~68-76. ISSN~1368-8375. Dostupné z: https://dx.doi.org/10.1016/j.oraloncology.2017.09.009.

Podrobný výpis o publikaci